mazdutide Updated Nov 6
Watch OPKO's quarterly royalty revenue from mazdutide as a gauge of China commercial uptake. Innovent's product revenue grew over 40% YoY in Q3 2026, but OPKO's specific royalty share is not separately disclosed. No near-term binary catalyst exists for this asset; the next potential catalyst would be Eli Lilly announcing a US Phase 3 program or FDA filing, which is not expected before 2027-2028.
- Mazdutide is the world's first approved GLP-1/glucagon dual agonist, a novel mechanism that showed 14-20% weight loss in Phase 3 China trials (GLORY-1 and GLORY-2), potentially differentiating it from single-mechanism competitors.
- China approved mazdutide for both weight management (June 2025) and type 2 diabetes (September 2025), giving it a large addressable market in a country with high obesity and diabetes prevalence.
- Innovent reported Q3 2026 product revenue exceeding RMB 4.7 billion (over 40% YoY growth), with mazdutide cited as a key growth driver, suggesting accelerating commercial uptake.
- OPKO is a passive royalty holder, not the developer; Eli Lilly and Innovent control commercialization, pricing and supply, leaving OPKO with no operational influence over mazdutide's success.
- Royalty revenue is still small: Q4 2025 generated only $4.3 million for OPKO, a negligible contribution relative to the company's overall revenue and operating losses.
- OPKO has already borrowed $125 million against future mazdutide royalty streams (August 2026), capping total repayment at 1.5x funded, which limits the upside OPKO can capture from the royalty stream.